Black Hills Regional Eye Institute

Summary

Black Hills Regional Eye Institute is a medical facility located in Rapid City, South Dakota. This center is recognized for care of Macular Degeneration, Age-Related Macular Degeneration, Diabetic Macular Edema, Glaucoma, Dry Eye Syndrome and other specialties. Black Hills Regional Eye Institute is involved with conducting 83 clinical trials across 56 conditions. There are 2 research doctors associated with this hospital, such as Adam Jorgensen, MD and Stephen Khachikian, M.D..

Top PIs

Clinical Trials running at Black Hills Regional Eye Institute

Age-Related Macular Degeneration

Macular Degeneration

Choroidal Neovascularization

Retinal Degeneration

Retinal Disease

None

Choroidal neovascularization

Wet AMD

Neurotrophic Keratopathy

RGX-314 Gene Therapy

for Age-Related Macular Degeneration

This trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. The goal is to reduce the need for regular treatments by helping the eye produce its own protective proteins. This could make treatment easier and more effective for patients.

Recruiting

2 awards

Phase 3

2 criteria

4D-150 + EYLEA

for Age-Related Macular Degeneration

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Recruiting

2 awards

Phase 3

4 criteria

RGX-314 Gene Therapy

for Wet Age-Related Macular Degeneration

This trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. It aims to help the eye make its own medicine to stop harmful blood vessels from causing vision loss. This could reduce the need for regular injections. RGX-314 modifies the retina's cells to create a treatment that may only be needed once.

Recruiting

1 award

Phase 2 & 3

6 criteria